A Phase II, Uncontrolled Pilot Trial to Evaluate That a Single Dose of 100 microg or 150 microg Org 36286 (Corifollitropin Alfa) is Able to Induce Multiple Follicular Growth During the First Week of Controlled Ovarian Stimulation for IVF [in-vitro fertilisation] or ICSI [intracytoplasmic sperm injection] Using a Long Protocol of GnRH [gonadotropin-releasing hormone] Agonist (Study 38833)

Trial Profile

A Phase II, Uncontrolled Pilot Trial to Evaluate That a Single Dose of 100 microg or 150 microg Org 36286 (Corifollitropin Alfa) is Able to Induce Multiple Follicular Growth During the First Week of Controlled Ovarian Stimulation for IVF [in-vitro fertilisation] or ICSI [intracytoplasmic sperm injection] Using a Long Protocol of GnRH [gonadotropin-releasing hormone] Agonist (Study 38833)

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2014

At a glance

  • Drugs Corifollitropin alfa (Primary)
  • Indications Infertility
  • Focus Therapeutic Use
  • Acronyms Realize
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 07 Oct 2009 Schering-Plough added as trial sponsor, affiliate and lead trial centre as reported by ClinicalTrials.gov.
    • 01 Jul 2009 Results have been presented at the European Society of Human Reproduction and Embryology, according to a Schering-Plough media release.
    • 19 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top